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Should Consistency Be a New Target?*Usman Baber, MD, MS, Jonathan L. Halperin, MDSEE PAGE 1539T he association of total and low-density lipo-protein cholesterol (LDL-C) blood levelswith cardiovascular disease (CVD) risk was
ﬁrst reported in the middle of the 20th century (1).
After several other types of lipid-lowering drugs
were proved to be unsafe or only equivocally effec-
tive, statins consistently produced large beneﬁts in
primary and secondary CVD prevention trials, vali-
dating the epidemiologic link between association
and causality, and raising LDL-C from the ranks of
risk marker to a clear risk factor for CVD. Still,
LDL-C has been viewed clinically as a categorical
value used to classify patients as having high,
borderline, or optimal levels on the basis of a single
measurement. As with most biological systems,
serum lipoprotein levels are dynamic, reﬂecting a
complex homeostatic integration of cholesterol syn-
thesis, intestinal absorption, hepatic clearance, and
fecal excretion. Although a host of clinical, meta-
bolic, and genetic factors contribute to LDL-C vari-
ability, the extent to which this inﬂuences CVD risk
has not been thoroughly examined. This could have
particular clinical relevance to patients who remain
at risk of atherothrombotic events despite high-
intensity statin therapy.
In this issue of the Journal, Bangalore et al. (2)
address this gap with ﬁndings from a post-hoc anal-
ysis of the randomized TNT (Treat to New Targets)
trial, which compared atorvastatin 80 and 10 mg daily*Editorials published in the Journal of the American College of Cardiology
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disclose.in patients with coronary artery disease (CAD) and
LDL-C levels <130 mg/dl. The authors evaluated the
relationship between LDL-C variability and cardio-
vascular events in 9,572 patients with at least 1 post-
baseline measurement of LDL-C. Variability was
quantiﬁed in terms of SD, average successive vari-
ability, coefﬁcient of variation, and variability inde-
pendent of the mean. By each method, greater
variability in LDL-C was associated with higher risks
of coronary and other cardiovascular events. The
connection persisted after controlling for atorvastatin
dosage and mean serum LDL-C levels, remaining
consistent in several sensitivity analyses, including
those adjusted for statin compliance as a time-
dependent covariate.The concept that LDL-C variability correlates with
CVD risk forces us to reconsider the prevailing ther-
apeutic standard under which statin therapy has been
focused on lowering average LDL-C levels. For some
physiological variables, such as heart rate, variability
is a function of healthy physiological ﬂux (3), whereas
for others, such as blood pressure in patients with
cerebral ischemia, variability is associated with an
incremental risk of stroke and death (4). Mechanistic
relationships between heart rate and autonomic tone
and between hypertension and stroke provide bio-
logically plausible rationales (5,6). Findings from the
study by Bangalore et al. (2) suggest that LDL-C
variability may be related to increased CVD risk
in patients treated with atorvastatin through
nonatherosclerotic mechanisms. More speciﬁcally,
whereas hazard ratios associated with treatment ef-
fect and mean LDL-C were not independent of one
another, LDL-C variability remained an independent
predictor of both coronary and cardiovascular end-
points in fully adjusted analyses, suggesting that
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variability to CVD risk.
How can the increased CVD risk associated with
LDL-C variability be explained? One possibility is that
LDL-C variability is a marker of the overall beneﬁt, or
lack of beneﬁt, that accrues from the pleiotropic effects
of statins. In other words, ﬂuctuating levels of serum
LDL-C amongpatients treatedwith statinsmay parallel
ﬂuctuations in other biological processes inﬂuenced
by therapy. Statins improve arterial stiffness and lower
central aortic blood pressure (7), which are risk factors
for left ventricular hypertrophy, heart failure, and
myocardial ischemia. These drugs also reduce in-
ﬂammation, which also has been linked to blood
pressure variability in animal models (8), and in
patients with hypertension and multiple vascular risk
factors in the placebo-controlled ASCOT-BPLA (Anglo-
Scandinavian Cardiac Outcomes Trial-Blood Pressure
Lowering Arm), treatment with atorvastatin 10 mg
daily reduced blood pressure variability (9). The study
by Bangalore et al. (2) found less variability in LDL-C in
patients treated with atorvastatin 80 mg daily than
with 10 mg daily, and greater suppression of unmea-
sured biological pathways could occur with higher-
intensity therapy as well.
Variability in LDL-C levels also may reﬂect behav-
ioral or clinical factors that impair responsiveness to
statins, the most obvious of which is inconsistent
adherence to treatment (10). The authors attempted to
control for this source of variability by selecting ran-
domized trial participants, and the ﬁndings will need
conﬁrmation in patients whose behavior and re-
sponses can be broadly generalized to those encoun-
tered in routine clinical practice (11). Genetic
polymorphisms in alleles that regulate the functions ofthe LDL-C receptor, HMG-CoA reductase, and apoli-
poprotein E, among others, also may account for var-
iable reductions in LDL-C in statin-treated patients
(12–14). The overall contribution of these traits seems
modest, however, and uncommonly exceeds clinical
characteristics like sex, body mass, and smoking in
their impact on statin responsiveness (14,15).
Even without a clear mechanistic explanation,
these new data suggest that the variability in LDL-C
levels over time has prognostic importance in statin-
treated patients. This information may eventually
inform clinical practice, guiding dosing intervals or
stain formulations to enhance stability. Although
reﬁning risk estimates and optimizing therapy are
goals pertinent to the care of patients who reliably take
medications as prescribed, we should bear in mind
that statin use remains low among even high-risk
patients, and broadly so in low- to middle-income
countries. Among Medicare beneﬁciaries with coro-
nary heart disease, Rosenson et al. (16) found that only
35% ﬁlled a high-dose statin prescription in the
ensuing year, and in low-income countries, Yusuf et al.
(17) showed that only 3.3% of patients with self-
reported CVD were taking statins. These sobering
statistics invite questions about whether innovative
approaches to initiation, awareness, and adherence,
such as polypills (18), might have a greater effect on
medical economics and health promotion than stra-
tegies focused on dose adjustment.
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